Chinese Academy of Medical Sciences
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2004-07-08
- Employees
- -
- Market Cap
- -
Comparative Effectiveness of PAL Based-therapy as Initial ET Versus PAL Based-therapy After ChT for HR+/HER2- ABC
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 400
- Registration Number
- NCT05343117
- Locations
- 🇨🇳
The Third Medical Center of PLA General Hospital, Beijing, Beijing, China
🇨🇳The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳Beijing Shijitan Hospital, Beijing, Beijing, China
A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT05318339
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 70
- Registration Number
- NCT05291910
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy Of Medical Sciences, Beijing, China
Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study
- Conditions
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 500
- Registration Number
- NCT05287308
- Locations
- 🇨🇳
Cancer Hospital, ChineseAMS, Beijing, Beijing, China
FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced Stage
- Conditions
- Interventions
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT05279677
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 54
- Registration Number
- NCT05254899
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT05235100
- Locations
- 🇨🇳
Radiotherapy Department of Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Preoperative Ultra-hypofractionated Radiotherapy Followed by Surgery for Retroperitoneal Sarcoma
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 28
- Registration Number
- NCT05224934
- Locations
- 🇨🇳
Radiotherapy Department of Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Years and Above (6 Months After Two Doses)
- Conditions
- Interventions
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2022-05-23
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 480
- Registration Number
- NCT05216484
- Locations
- 🇨🇳
Xiangyang City Centers for Disease Control and Prevention, Xiangyang, Hubei, China
Temozolomide for Injection Combined With Epirubicin in First-line Treatment of Leiomyosarcoma
- Conditions
- Interventions
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 28
- Registration Number
- NCT05204524
- Locations
- 🇨🇳
Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, Beijing, China